Natera
NTRA
$212.73
-2.78%
Natera, Inc. is a diagnostic and research company operating in the healthcare sector, specifically within medical diagnostics and research. It leverages proprietary molecular and bioinformatics technology to develop and commercialize non-invasive tests, with key products including the Panorama Non-Invasive Prenatal Test (NIPT), Horizon Carrier Screening (HCS), the Signatera molecular residual disease (MRD) test for cancer monitoring, and the Prospera test for organ transplant rejection assessment. The company is positioned as a technology-driven disruptor in the genomics and personalized medicine space, aiming to expand the utility of cell-free DNA testing across multiple clinical domains. The current investor narrative is heavily focused on the company's path to sustainable profitability, driven by robust revenue growth, particularly in its oncology and transplant segments, alongside ongoing debates about its valuation and the scalability of its growth amidst significant operating investments.…
NTRA
Natera
$212.73
Related headlines
Investment Opinion: Should I buy NTRA Today?
Rating & Thesis: We assign a Hold rating. The core thesis is that NTRA's compelling growth story and path to profitability are now balanced by a full valuation, creating a asymmetric risk/reward profile where the upside is priced in and the downside from missed expectations is significant. While analyst sentiment is bullish, the stock's proximity to its 52-week high and rich multiples warrant caution.
Supporting Evidence: The stock trades at a Price-to-Sales ratio of 13.6x, a premium multiple that demands flawless execution. While Q4 revenue grew 39.8% YoY and the company turned a net profit of $47.3 million, the forward PE remains deeply negative at -590.7, indicating earnings are not yet stabilizing. Positive free cash flow of $96.6M (TTM) and a strong balance sheet (D/E of 0.125) are supportive, but the stock's 1-month surge of 14.7% has likely front-run near-term positive catalysts.
Risks & Conditions: The two biggest risks are a growth deceleration below 30% and a return to quarterly losses. This Hold rating would upgrade to a Buy if the PS ratio compressed below 10x while growth remained above 35%, or if the company reported a second consecutive quarter of net income above $40 million, confirming the profitability inflection. It would downgrade to a Sell if revenue growth decelerated below 25% or if quarterly net income turned negative again. At current levels, the stock is fairly valued relative to its own compressed historical multiples but remains overvalued on a fundamental earnings basis, trading on future promises rather than current profits.
Sign up to view all
NTRA 12-Month Price Forecast
The outlook is balanced with a tilt towards the base case. The recent quarterly profit is a major positive, but it's a single data point in a history of losses. The stock's 14.7% surge over the past month suggests optimism may be getting ahead of itself, leaving limited near-term upside without flawless execution. We would upgrade to a bullish stance on confirmation of a second consecutive profitable quarter and maintenance of >35% revenue growth. A downgrade to bearish would be triggered by a return to losses or growth deceleration below 25%, either of which would likely cause a violent derating given the current premium valuation.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $276.55 and implied upside of +30.0% versus the current price.
Average Target
$276.55
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$170 - $277
Analyst target range
Natera is covered by a limited cohort of 6 analysts, indicating it is still evolving in terms of broad institutional coverage. The consensus sentiment leans bullish, as evidenced by recent institutional ratings which include actions like 'Overweight' from Morgan Stanley and 'Outperform' from Baird and Evercore ISI. While a precise consensus recommendation string and average target price are not provided in the analyst data, the pattern of recent actions suggests a positive bias. The implied upside or downside cannot be calculated without an average target, but the recent price strength aligns with positive analyst sentiment. The target range can be inferred from revenue estimates, with the average estimated revenue for the forward period at $5.202 billion, ranging from a low of $5.025 billion to a high of $5.350 billion. A wide spread in these estimates signals some uncertainty around the exact growth trajectory. The high-end estimate likely assumes successful further penetration in oncology and transplant markets, along with potential new test launches or favorable reimbursement decisions. The low-end estimate may factor in increased competition, pricing pressure, or slower-than-expected adoption. The limited number of covering analysts means price discovery can be less efficient and more volatile, but the consistent 'Buy' or 'Outperform' ratings from those who do cover it provide a supportive signal for the growth narrative.
Bulls vs Bears: NTRA Investment Factors
The bull case, centered on a demonstrable inflection to profitability alongside sustained 40% revenue growth, currently holds stronger evidence. The Q4 net income of $47.3 million is a pivotal data point that validates the scalability of Natera's business model. However, the bear case is anchored in the extreme valuation multiples, which price in flawless execution of this growth for years to come. The single most important tension in the investment debate is whether the company can consistently deliver quarterly profits to justify its premium sales multiple of 13.6x, or if any stumble in growth or margins will trigger a severe derating given its high beta of 1.57.
Bullish
- Inflection to Profitability: Natera achieved a landmark quarterly net income of $47.3 million in Q4 2025, a dramatic swing from a loss of $87.5 million in Q3. This demonstrates the company's ability to translate its 40% revenue growth into bottom-line results, signaling a potential sustainable profit trajectory.
- Exceptional Revenue Growth: Revenue grew 39.8% YoY to $665.5 million in Q4 2025, with consistent sequential growth throughout the year. This hyper-growth, far exceeding typical sector rates, validates strong demand for its oncology and transplant tests and underpins the high-growth investment thesis.
- Strong Balance Sheet & FCF: The company has a robust balance sheet with a low debt-to-equity ratio of 0.125 and a high current ratio of 3.39. It also generated $96.6 million in TTM free cash flow, providing significant financial flexibility to fund growth without dilutive financing.
- Positive Analyst Sentiment: Covering analysts from firms like Morgan Stanley, Baird, and Evercore ISI have issued 'Overweight' or 'Outperform' ratings, indicating institutional confidence in the growth story. The average forward revenue estimate of $5.20 billion suggests continued strong growth expectations.
Bearish
- Extreme Valuation on Earnings: Despite recent profitability, the stock trades at a trailing PE of -150.5 and a forward PE of -590.7, reflecting a market pricing based on distant future earnings. This leaves the stock vulnerable to significant multiple compression if growth decelerates.
- High Volatility & Market Sensitivity: With a beta of 1.567, NTRA is approximately 57% more volatile than the broader market. This was evidenced by a sharp 28.2% maximum drawdown in the recent period, indicating high risk for investors with low risk tolerance.
- Profitability Not Yet Sustained: The Q4 profit of $47.3 million follows three consecutive quarterly losses in 2025. Return on Equity remains deeply negative at -12.16% on a trailing basis, indicating cumulative shareholder value destruction has not yet been fully reversed.
- Limited Analyst Coverage: Only 6 analysts cover the stock, which can lead to less efficient price discovery and higher volatility. The wide range in forward revenue estimates ($5.03B low to $5.35B high) also highlights uncertainty around the precise growth trajectory.
NTRA Technical Analysis
The prevailing price trend for Natera has been a volatile consolidation within a broad range over the past six months, following a significant 41.33% gain over the prior year. As of the latest close at $223.37, the stock is trading approximately 87% of the distance from its 52-week low of $131.81 to its high of $256.36, indicating it is positioned closer to the upper end of its annual range but not at a new high. This suggests the stock retains momentum from its longer-term uptrend but may be encountering resistance near previous peaks. Recent short-term momentum shows a sharp divergence, with a strong 14.70% gain over the past month contrasting with a more modest 7.37% gain over three months and a 6.47% decline over six months. This 1-month surge, which significantly outperformed the SPY's 6.31% gain, indicates a potential reacceleration of bullish sentiment, possibly driven by recent quarterly results, though it follows a period of weakness earlier in the year. Key technical levels are clearly defined by the 52-week high at $256.36, which serves as major overhead resistance, and the 52-week low at $131.81, representing a distant but critical support floor. A decisive breakout above $256.36 would signal a resumption of the primary uptrend, while a breakdown below recent lows around $182.65 could indicate a deeper correction. The stock's beta of 1.567 confirms it is approximately 57% more volatile than the broader market, which is critical for risk assessment as it implies larger price swings in both directions.
Beta
1.57
1.57x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$132-$256
Price range past year
Annual Return
+32.4%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | +2.6% | +5.4% |
| 3m | +4.8% | +10.9% |
| 6m | -12.1% | +11.0% |
| 1y | +32.4% | +28.1% |
| ytd | -7.0% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory is exceptionally strong, with Q4 2025 revenue reaching $665.5 million, representing a 39.79% year-over-year growth rate. This acceleration is evident when comparing sequential quarters; revenue grew from $501.83 million in Q1 2025 to $665.5 million in Q4 2025, demonstrating consistent quarter-over-quarter expansion. Segment data shows the vast majority of revenue, $661.16 million, comes from product sales, with only $4.34 million from licensing, underscoring the commercial scale of its core testing services. This robust growth trajectory supports the investment thesis centered on market penetration and test adoption. Regarding profitability, the company achieved a landmark net income of $47.258 million in Q4 2025, marking a significant inflection from losses in prior quarters, such as a net loss of $87.544 million in Q3 2025. Gross margin remains healthy at 67.14% for the quarter, consistent with the trailing gross margin of 64.85% from valuation data. The progression from substantial operating losses to quarterly profitability, as seen in the operating income improving from -$97.576 million in Q3 to -$22.786 million in Q4, indicates aggressive margin expansion and operational leverage as revenue scales. The balance sheet and cash flow position is solid, with a strong current ratio of 3.39 and a very low debt-to-equity ratio of 0.125, indicating minimal financial leverage and ample liquidity. The company generated $96.613 million in trailing twelve-month free cash flow, demonstrating an ability to fund operations and growth internally. Return on equity remains negative at -12.16% on a trailing basis, reflecting the cumulative impact of prior investment periods, but the positive net income and FCF suggest this metric is poised for a rapid improvement.
Quarterly Revenue
$665500000.0B
2025-12
Revenue YoY Growth
+0.39%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$96613000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Given Natera's recent quarterly net income of $47.258 million is positive, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is deeply negative at -150.47, reflecting the company's history of losses, while the forward PE is also negative at -590.72, based on estimated EPS. The gap between these figures is distorted by the recent shift to profitability; the market is valuing the stock on future growth expectations beyond the next twelve months, as near-term analyst EPS estimates of $4.89 suggest a forward PE in the mid-40s if annualized, indicating high growth expectations. Compared to industry averages, Natera trades at a significant sales multiple premium, with a Price-to-Sales (PS) ratio of 13.58. While specific industry average PS data is not provided in the valuation set, such a high multiple is typical for high-growth, disruptive diagnostic companies but demands sustained hyper-growth to justify. The premium is likely attributed to its superior revenue growth rate of nearly 40% and its pioneering position in MRD testing. Historically, the stock's own valuation has compressed from extreme levels; its current PS ratio of 13.58 is down substantially from a PS ratio of 47.06 recorded at the end of Q4 2025, as per historical ratios data. This indicates the stock has de-rated from its peak multiples, trading now at a more moderate level within its own historical range, which may balance optimism about growth with a more realistic assessment of future scalability and competition.
PE
-150.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -124x~166x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-115.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation compression, as the stock trades at a premium Price-to-Sales ratio of 13.6x based on expectations of sustained hyper-growth near 40% YoY. A deceleration in revenue growth below 30% could trigger a significant multiple contraction. While the balance sheet is strong, the company's recent history of losses (trailing ROE of -12.2%) means profitability is not yet a proven trend, and a return to quarterly losses would undermine investor confidence. Furthermore, revenue is highly concentrated in product sales ($661.2M of $665.5M in Q4), creating dependence on test volume and reimbursement rates without a diversified income stream.
Market & Competitive Risks: Natera faces intense competition in the genomics and diagnostic space, where technological disruption is constant. Its high beta of 1.567 makes it highly sensitive to broader market downturns and sector rotations away from high-growth, high-multiple stocks. Regulatory headwinds, such as changes to Medicare reimbursement for its MRD or transplant tests, could materially impact revenue growth and margins. The stock's volatility is evident in its 28.2% max drawdown over the past six months, showing it is prone to sharp corrections even amidst a long-term uptrend.
Worst-Case Scenario: The worst-case scenario involves a 'growth scare' where quarterly revenue growth decelerates sharply (e.g., to sub-20%) concurrent with a return to net losses, triggering a simultaneous derating of its PS multiple and a loss of growth investor interest. This could be exacerbated by a broader market sell-off impacting high-beta stocks. In this adverse scenario, the stock could realistically revisit its 52-week low of $131.81, representing a downside of approximately -41% from the current price of $223.37. Such a drawdown is plausible given the stock's historical volatility and the high expectations embedded in its valuation.
FAQ
The key risks are, in order of severity: 1) Valuation Risk: The high PS ratio of 13.6x makes the stock vulnerable to multiple compression if growth slows. 2) Execution Risk: Profitability is not yet proven, with only one recent profitable quarter after a history of losses (trailing ROE -12.2%). 3) Competitive/Market Risk: Intense competition in genomics and a high beta of 1.567 expose it to sector rotations and market downturns, evidenced by a 28.2% max drawdown recently. 4) Regulatory Risk: Revenue depends heavily on favorable insurance reimbursement for its tests, which is subject to change.
Our 12-month forecast outlines three scenarios. The Base Case (55% probability), with a target range of $210-$256, assumes revenue grows ~30-35% in line with analyst estimates and intermittent profitability, keeping the stock range-bound. The Bull Case (25% probability), targeting $256-$300, requires sustained >35% growth and consistent profits, driving a re-rating. The Bear Case (20% probability), targeting $132-$190, involves growth deceleration below 25% and a return to losses, triggering a severe derating. The Base Case is most likely, centered on the company's current execution trajectory but acknowledging the high bar set by its valuation.
NTRA is fairly valued relative to its own compressed historical multiples but overvalued on a fundamental earnings basis. Its trailing PE is deeply negative at -150.5, and its forward PE is also negative, meaning the market is valuing it purely on sales growth. A PS ratio of 13.6x is a premium multiple, justified only by its exceptional 39.8% revenue growth. Compared to a more mature diagnostic peer, this is expensive. The valuation implies the market expects sustained hyper-growth and rapid margin expansion. Any stumble would likely cause a significant derating, as seen when its PS fell from 47x to current levels.
NTRA is a compelling but risky investment. For aggressive growth investors comfortable with high volatility (beta of 1.57), the company's 40% revenue growth and recent turn to profitability ($47.3M net income in Q4) are strong positives. However, at a Price-to-Sales ratio of 13.6x, much of this potential is already priced in. The stock is a good buy only for those who believe the company can consistently deliver on its growth promises and expand margins further. For most investors, the current risk/reward is balanced, making it more appropriate to hold and monitor rather than initiate a new position after its 14.7% one-month surge.
NTRA is primarily suitable for long-term investors (3-5 year horizon) who can withstand significant volatility. The company is in a capital-intensive growth phase, investing heavily to capture market share in oncology and transplant testing. Short-term trading is hazardous due to the stock's high beta (1.567) and sensitivity to quarterly earnings surprises. There is no dividend, eliminating an income component. The investment thesis is based on the long-term adoption of its MRD and transplant rejection tests, which will take years to fully play out. A minimum holding period of 18-24 months is suggested to weather volatility and allow the growth narrative to develop.
